Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-025279
Filing Date
2020-05-14
Accepted
2020-05-14 08:31:37
Documents
63
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vcnx-10q_20200331.htm 10-Q 1163048
2 EX-10.6 vcnx-ex106_224.htm EX-10.6 138742
3 EX-31.1 vcnx-ex311_178.htm EX-31.1 16706
4 EX-31.2 vcnx-ex312_177.htm EX-31.2 16652
5 EX-32.1 vcnx-ex321_176.htm EX-32.1 7289
6 GRAPHIC gso1yy5rhbji000001.jpg GRAPHIC 4083
  Complete submission text file 0001564590-20-025279.txt   4403153

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT vcnx-20200331.xml EX-101.INS 753827
8 XBRL TAXONOMY EXTENSION SCHEMA vcnx-20200331.xsd EX-101.SCH 42794
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vcnx-20200331_cal.xml EX-101.CAL 29087
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vcnx-20200331_def.xml EX-101.DEF 131472
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE vcnx-20200331_lab.xml EX-101.LAB 328613
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vcnx-20200331_pre.xml EX-101.PRE 251675
Mailing Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620
Business Address 1895 MOUNT HOPE AVE ROCHESTER NY 14620 585-271-2700
VACCINEX, INC. (Filer) CIK: 0001205922 (see all company filings)

EIN.: 161603202 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38624 | Film No.: 20875403
SIC: 2834 Pharmaceutical Preparations